Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
U.S. FDA approves Aromasin for adjuvant treatment of early breast cancer in postmenopausal women
November 3rd, 2005
Pfizer, Inc., has received approval from the U.S. Food & Drug Administration (FDA) to market Aromasin (exemestane tablets) for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer following 2-3 years of tamoxifen for a completion of 5 consecutive years of adjuvant hormonal therapy. The approval was based on the Intergroup Exemestane Study (IES) which showed that patients who switched to Aromasin after 2-3 years of tamoxifen, for a combined total of 5 years of therapy, had 31% more protection from cancer recurrence than those who remained on 5 years of tamoxifen therapy. This landmark study, published in the...
Source: Women's Health Weekly (2005-11-03)
|
